Text Size

Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women

This study has been completed.
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT01011725
First received: November 10, 2009
Last updated: NA
Last verified: November 2009
History: No changes posted

November 10, 2009
November 10, 2009
November 2005
April 2006   (final data collection date for primary outcome measure)
  • Number of subjects with Clinical Adverse Events (CAE) [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]
  • Number of subjects with Serious CAEs [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]
  • Number of subjects with drug-related CAEs [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]
  • Number of subjects with serious drug-related CAEs [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]
  • Number of subjects that discontinued with CAEs [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]
  • Number of subjects with Laboratory Adverse Events (LAE) [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]
  • Number of subjects with drug-related LAEs [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]
  • Number of subjects with serious LAEs [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]
  • Number of subjects with serious drug-related LAEs [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]
  • Number of subjects that discontinued with LAEs [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Efficacy of MK0773 in Healthy Postmenopausal Women

This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic efficacy of MK0773 in healthy postmenopausal women.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Body Composition
  • Drug: MK0773
    25 mg oral tablet b.i.d. MK0773 or 100 mg oral tablet b.i.d. MK0773, for 12 weeks
  • Drug: Placebo
    Placebo oral tablet b.i.d for 12 weeks
  • Experimental: 1
    MK0773
    Intervention: Drug: MK0773
  • Placebo Comparator: 2
    Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
66
March 2009
April 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject is a nonsurgical postmenopausal female
  • Subject is neither grossly overweight nor underweight for her height
  • Subject is in good health
  • Subject is willing to avoid excess alcohol and strenuous physical activity during the study
  • Subject agrees to refrain from consuming St. John's Wort, grapefruit or grapefruit juice during the study

Exclusion Criteria:

  • Subject has significant drug allergies
  • Subject has donated blood or taken an investigational drug in another clinical trial within the last 4 weeks
  • Subject is a regular user or past abuser of any illicit drug (including alcohol)
  • Subject drinks excessive amounts of caffeinated beverages
  • Subject has a history of cancer
Female
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01011725
2009_687, MK0773-003
No
Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc.
Merck
Not Provided
Study Director: Medical Monitor Merck
Merck
November 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP